Related Experiment Video
Updated: Sep 28, 2025
05:41
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
3.0K
Clinical settings with tofacitinib in ulcerative colitis.
Carlos Taxonera1, Daniel Carpio López2, Ana Cabez Manas3
1Aparato Digestivo, Hospital Clínico Universitario San Carlos, España.
Revista Espanola De Enfermedades Digestivas
|April 4, 2022
Summary
Tofacitinib offers a unique oral treatment for ulcerative colitis (UC) with rapid action and efficacy, regardless of prior biologic exposure. Its manageable safety profile supports use in specific patient scenarios.
Area of Science:
- Gastroenterology and Immunology
- Pharmacology
Background:
- Ulcerative colitis (UC) treatment landscape includes various therapeutic options.
- Janus kinase (JAK) inhibitors represent a distinct class of drugs for immune-mediated diseases.
- Tofacitinib, an oral JAK inhibitor, presents unique characteristics compared to traditional therapies.
Purpose of the Study:
- To review the distinct features of tofacitinib for ulcerative colitis (UC) management.
- To evaluate tofacitinib's efficacy and safety profile in diverse UC patient populations.
- To define specific clinical scenarios where tofacitinib offers advantages.
Main Methods:
- Review of existing clinical evidence and pharmacological data on tofacitinib.
- Analysis of tofacitinib's pharmacokinetic properties, including oral administration and short half-life.
- Assessment of immunogenicity and safety profiles of tofacitinib in UC patients.
Main Results:
- Tofacitinib demonstrates rapid onset of action and flexibility in UC treatment.
- Efficacy is observed in patients regardless of prior exposure to anti-TNF drugs or other biologics.
- The safety profile is known and manageable with appropriate precautions.
Conclusions:
- Tofacitinib offers a valuable oral therapeutic option for ulcerative colitis.
- Its distinct properties make it suitable for patients with prior treatment failures or intolerance.
- Consideration for concurrent immune-mediated diseases and need for rapid response are key scenarios for tofacitinib use.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
256
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
256
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:29Inflammatory Bowel Disease IV: Pharmacological Management
216
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
216
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
231
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
231
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
249
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
385
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
385